Regan Andrew has amended a previous filing to provide updated information regarding his ownership and a recent reverse stock split involving CDT Equity Inc. This amendment is significant as it reflects ongoing changes in corporate structure and ownership within the pharmaceutical preparations sector.

In the filing dated October 27, 2026, Andrew, who serves as the Chief Executive Officer of Corvus Capital Ltd., clarified details surrounding his ownership of shares in CDT Equity Inc. The amendment was necessary to reflect a 1-for-10 reverse stock split of the outstanding shares of common stock that took effect on July 20, 2026.

Background

Regan Andrew is the Chief Executive Officer of Corvus Capital Ltd., which is involved in various investment activities. The company is associated with CDT Equity Inc., a firm engaged in the pharmaceutical preparations industry, as indicated by its Standard Industrial Classification (SIC) code of 2834. CDT Equity Inc. was previously known as Conduit Pharmaceuticals Inc. before its name change on September 22, 2023. The recent filing history shows a series of amendments and updates, including the original Form 4 submitted on September 2, 2026.

What the Filing Says

The recent filing states, "This Form 4 Amendment (the 'Amendment') is being filed to amend the Form 4 filed by Dr. Andrew Regan on September 2, 2026, to reflect the 1-for-10 reverse stock split of the outstanding shares of common stock..." It also notes the addition of Corvus Capital Ltd. as a filer due to its status as a 10% owner at the time of the original filing.

Impact

This amendment may affect various stakeholders, including shareholders of CDT Equity Inc. and investors in the pharmaceutical preparations sector. The filing indicates that Corvus Capital Ltd. holds a significant stake in CDT Equity, which could influence future corporate decisions and strategies.

What's Next

The filing does not say what happens next.